WNK1 and hepatocellular carcinoma: Treatment of SLC12A1 antagonist Bumetanide can inhibit HCC growth both in vitro and in vivo, indicating the targeted therapeutic value for blocking the NKCC2–WNK1–ERK5 axis [61].